GenFleet Therapeutics のニュースと活動
バイオテクノロジー
GenFleet TherapeuticsはEurofins (ルクセンブルグ大公国),Lonza (スイス連邦),Genus (英国)を含む2,350の競合企業を有します。
Popular M&A news in バイオテクノロジー
- Transcarent and Accolade have merged (2025年4月9日に公開)..
- ％sは、％s百万ドルの資金調達を発表しました。 (2025年4月7日に公開).
- ％sは、％s百万ドルの資金調達を発表しました。 (2025年4月4日に公開).
バイオテクノロジー業界でのその他のコンタクトの提案
ニュース
％sによる最新のプレスリリース
- Updated Results from Phase II Registrational Study of Fulzerasib Monotherapy Orally Presented at the 2024 World Conference on Lung Cancer-GenFleet Therapeutics
- GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation-GenFleet Therapeutics
- GenFleet Therapeutics Finishes Dosing of the First Patient with GFH375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China-GenFleet Therapeutics
- GenFleet Receives IND Approval from China’s NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation-GenFleet Therapeutics
- GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO
- GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer-GenFleet Therapeutics
- GenFleet Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting-GenFleet Therapeutics
- GenFleet Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting-GenFleet Therapeutics
- GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma -GenFleet Therapeutics
- GFH009 Receives FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia-GenFleet Therapeutics
- View more press releases Close
％sについてのソーシャルメディア
- GenFleet Therapeutics についてのウィキペディア,Google News & Yahoo Financeの記事
- GenFleet Therapeutics についてのLinkedIn,ツイッター & YouTubeの記事
